Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|September 1, 2016
Automated Method Optimization
CLICK FIGURE TO ENLARGEChromLab Software makes purifying protei
Advertisement
ChromLab Software makes purifying proteins easier on the NGC Chromatography System. It provides intuitive navigation to all key functions, has method templates to get you started quickly, and provides single-click analysis including peak integration and overlay.
Optimize purification conditions easily with ChromLab Software’s Scouting Wizard:
- With automated single parameter screeningWith reproducible, automated buffer creation using the buffer blending valve and the prepopulated buffer recipes
Advertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement